Form 4: Cartesian Therapeutics CMO Receives Equity Awards

Cartesian Therapeutics' Chief Medical Officer, Milos Miljkovic, was granted 27,000 restricted stock units and options for 77,000 shares of common stock.

Summary

• Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, Inc. (RNAC), acquired 27,000 shares of common stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• These RSUs will vest 25% on January 2, 2027, with the remainder vesting in three equal annual installments, fully vested by January 2, 2030.
• Miljkovic also acquired options to purchase 77,000 shares of common stock with an exercise price of $6.76 per share on January 2, 2026.
• These stock options will vest 25% on January 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, and expire on January 1, 2036.
• Following these transactions, Miljkovic beneficially owns 62,393 shares of common stock and 77,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports routine equity grants to a key executive, which is generally a positive for aligning management incentives with shareholder interests, but does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of equity awards aligns the Chief Medical Officer's interests with those of shareholders.
• The multi-year vesting schedule encourages long-term commitment and performance from a key executive.

Future Outlook

The grants of Restricted Stock Units and Employee Stock Options include multi-year vesting schedules, indicating a long-term incentive structure for the Chief Medical Officer, with full RSU vesting by January 2, 2030, and options expiring on January 1, 2036.

Industry Context

Equity grants, including Restricted Stock Units and stock options, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. They are designed to incentivize long-term performance and align executive interests with shareholder value creation, particularly in companies like Cartesian Therapeutics (RNAC) focused on therapeutic development.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for executive compensation is a common practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies such as Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity to attract and retain top talent.
• Multi-year vesting schedules, like the 3-4 year vesting for RSUs and options, are standard in the industry to ensure executive retention and incentivize sustained performance, aligning with best practices seen in companies developing complex therapeutic pipelines.
• The grant of equity at a $0 price for RSUs and a specific exercise price for options is typical for incentive awards, reflecting a common approach to executive compensation rather than a direct purchase.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Next Steps

• First tranche of Restricted Stock Units and Employee Stock Options will vest on January 2, 2027.
• Remaining Restricted Stock Units will vest in three equal annual installments until January 2, 2030.
• Remaining Employee Stock Options will vest in 36 equal monthly installments.

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Milos Miljkovic, Chief Medical Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation